Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study

BACKGROUND: Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of icatibant is not documented in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Caballero, Teresa, Zanichelli, Andrea, Aberer, Werner, Maurer, Marcus, Longhurst, Hilary J., Bouillet, Laurence, Andresen, Irmgard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870812/
https://www.ncbi.nlm.nih.gov/pubmed/29599966
http://dx.doi.org/10.1186/s13601-018-0195-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870812/
https://www.ncbi.nlm.nih.gov/pubmed/29599966
http://dx.doi.org/10.1186/s13601-018-0195-x

Ejemplares similares